Study guide

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions

Key Takeaways Explain This Topic AI

Pemphigus vulgaris causes flaccid blisters with mucosal involvement and a positive Nikolsky sign from intraepidermal desmoglein antibodies; bullous pemphigoid causes tense subepidermal blisters that usually spare the mouth.

Toxic epidermal necrolysis involves more than 30% of body surface area, Stevens-Johnson syndrome less than 10%, and the commonest triggers are allopurinol, anticonvulsants, sulfonamides and NSAIDs.

DRESS presents 2-8 weeks after the culprit drug with fever, rash, eosinophilia, lymphadenopathy and hepatitis.

Last updated: September 2026

Dermatology questions in MRCP(UK) Part 1 demand precise diagnostic pattern recognition, detailed knowledge of immunopathology, mastery of stepwise therapeutic ladders, and the immediate recognition of acute life-threatening dermatological emergencies. This section covers papulosquamous and eczematous disorders, immunobullous diseases, severe cutaneous adverse drug reactions (SCARs), and cutaneous malignancies.

  • 1. Papulosquamous & Eczematous Disorders
  • Psoriasis

Psoriasis is a chronic, immune-mediated inflammatory dermatosis affecting 2–3% of the UK population. It is driven by abnormal T-lymphocyte activation (Th1 and Th17 cytokines: IL-23, IL-17A, TNF-α), stimulating excessive epidermal keratinocyte proliferation. Keratinocyte transit time from the basal layer to the stratum corneum is reduced from 28 days to 3–5 days, resulting in epidermal hyperplasia ( acanthosis ) and premature, incomplete cornification with retention of keratinocyte nuclei in the stratum corneum ( parakeratosis ).

Clinical Subtypes:

Chronic Plaque Psoriasis (Psoriasis Vulgaris, ~90%): Symmetrically distributed, sharply demarcated, erythematous plaques covered with thick, micaceous silvery-white scales. Classic predilection for extensor surfaces (elbows, knees), scalp, sacrum, umbilicus, and natal cleft.

Auspitz Sign: Pinpoint bleeding elicited when surface scales are scraped off, caused by mechanical trauma to tortuous, dilated dermal capillaries within the thinned suprapapillary dermal plates.

Koebner Phenomenon (Isomorphic Response): Development of characteristic psoriatic lesions at sites of cutaneous injury or trauma (scars, scratches, burns).

Guttate Psoriasis: Widespread eruption of small (0.5–1.5 cm), 'teardrop-like' salmon-pink scaly papules over the trunk and proximal extremities. Typically affects children and young adults 1–3 weeks following an acute upper respiratory infection (Group A beta-haemolytic Streptococcus pharyngitis or tonsillitis) ; anti-streptolysin O (ASO) titre is elevated. Resolves spontaneously over 3–4 months or responds to phototherapy; ~30–50% progress to plaque psoriasis.

Pustular Psoriasis: Generalized pustular psoriasis (von Zumbusch): Life-threatening acute dermatosis presenting with widespread sheets of sterile, non-follicular pustules coalescing on an intensely erythematous, painful base. Accompanied by high fever, leukocytosis, and systemic toxicity. Classically triggered by the abrupt withdrawal of systemic corticosteroids.

Erythrodermic Psoriasis: Generalized inflammatory erythema involving >90% of total body surface area (BSA) . Medical emergency producing catastrophic physiological instability: high-output cardiac failure (from massive cutaneous vasodilation), severe hypothermia, fluid and protein loss, and secondary sepsis.

Psoriatic Nail Changes (in up to 50%):

Pitting: Punctate surface depressions caused by parakeratotic cell shedding from the proximal nail matrix.

Onycholysis: Painless separation of the nail plate from the underlying nail bed.

Subungual Hyperkeratosis: Accumulation of chalky scale beneath the distal nail.

'Oil Drop' / 'Salmon Patch' Discolouration: Red-yellow translucent discolouration of the nail bed.

Stepwise Management Ladder (NICE CG153):

Topical Therapy (First-line for localized plaque disease):

First-line: Once-daily potent topical corticosteroid (e.g. betamethasone dipropionate) PLUS once-daily topical vitamin D analogue (e.g. calcipotriol) applied together for up to 4 weeks (often prescribed as fixed-dose combination ointment/gel e.g. Dovobet).

Alternatives: Topical coal tar preparations, dithranol (short-contact therapy), or topical calcineurin inhibitors (tacrolimus) for sensitive facial/flexural areas.

Phototherapy (Second-line for widespread plaque or guttate disease):

Narrowband UVB (NB-UVB) phototherapy (3 times weekly).

Photochemotherapy ( PUVA : oral/bath Psoralen + UVA radiation); monitor lifetime exposure for non-melanoma skin cancer risk.

Oral Systemic Non-Biologic Agents (Third-line for extensive/refractory disease or severe arthritis):

Methotrexate: First-line systemic; dihydrofolate reductase inhibitor; co-prescribe folic acid (5 mg once weekly 24h post-dose). Monitoring: FBC, LFTs, Procollagen III Peptide (PIIINP) for hepatic fibrosis, CXR for pneumonitis.

Ciclosporin: Calcineurin inhibitor offering rapid disease control. Toxicities: Nephrotoxicity, hypertension; limited to 1–2 years of continuous use.

Acitretin: Oral retinoid, highly effective in pustular and erythrodermic psoriasis. TERATOGENICITY WARNING: Strictly contraindicated in women of childbearing potential. Pregnancy must be avoided for at least 3 years following treatment cessation due to long-lived active metabolite etretinate stored in fat.

Biologic Therapies (Fourth-line: PASI ≥10 and DLQI >10 refractory to systemic therapy):

Anti-TNF agents: Adalimumab, infliximab, etanercept.

Anti-IL-17A inhibitors: Secukinumab, ixekizumab.

Anti-IL-23 inhibitors: Guselkumab, risankizumab.

Anti-IL-12/23 inhibitor: Ustekinumab.

Mandatory Pre-Treatment Screening: Chest X-ray and IGRA (Quantiferon) to rule out latent tuberculosis, plus viral hepatitis B/C serology.

Atopic Eczema (Atopic Dermatitis)

Pathophysiology: Complex interplay of genetic skin barrier dysfunction and Th2 immune dysregulation. Loss-of-function mutations in the Filaggrin ( FLG ) gene impair stratum corneum integrity, increasing transepidermal water loss and allergen penetration. Associated with the 'atopic march' (eczema → food allergy → allergic rhinitis → asthma).

Clinical Features: Intractable pruritus, dry scaly erythema, excoriations, and lichenification (thickened, leathery skin with exaggerated markings from chronic rubbing). Classic flexural distribution (antecubital and popliteal fossae, neck, wrists, ankles) in older children and adults; infants display facial and extensor surface involvement.

Management: Liberal, frequent emollients; topical corticosteroids (mild to potent) for acute flares; topical calcineurin inhibitors ( tacrolimus, pimecrolimus ) for face/neck (avoiding corticosteroid-induced skin atrophy); systemic dupilumab (anti-IL-4Rα) or JAK inhibitors (upadacitinib, baricitinib) for severe refractory disease.

LIFE-THREATENING COMPLICATION — Eczema Herpeticum:

Disseminated cutaneous Herpes Simplex Virus (HSV-1) infection on eczema-affected skin.

Clinical Triad: High fever, systemic malaise, and a rapid eruption of monomorphic, clustered, 'punched-out' circular erosions and umbilicated pustules .

Emergency Action: Immediate oral or IV aciclovir . Temporarily withhold topical corticosteroids until systemic antiviral therapy is established. Urgent ophthalmology review if lesions involve the periorbital region (risk of dendritic corneal ulceration and scarring).

2. Immunobullous Diseases: Pemphigus vs Pemphigoid

Autoimmune blistering diseases are high-yield MRCP Part 1 questions. Differentiating Pemphigus Vulgaris from Bullous Pemphigoid requires mastery of blistering semiology, histopathology, and immunofluorescence:

Feature Pemphigus Vulgaris Bullous Pemphigoid

Target Antigen & Locus Desmoglein 3 (mucosa) and Desmoglein 1 (skin), components of epithelial desmosomes BP180 (type XVII collagen) and BP230 (dystonin), components of basement membrane hemidesmosomes

Blister Cleavage Plane Intraepidermal (suprabasal layer) Subepidermal (dermo-epidermal junction)

Microscopic Hallmark Acantholysis (loss of intercellular keratinocyte adhesions); basal cells remain attached to BM like a "row of tombstones" Intact blister roof of full-thickness epidermis with a dense eosinophil-rich dermal inflammatory infiltrate

Blister Semiology Flaccid, thin-walled, fragile bullae that rupture easily, leaving weeping, painful, non-healing denuded erosions Tense, firm, thick-walled bullae on an erythematous or urticarial base; resistant to rupture

Mucosal Involvement Severe & Universal (>90%) ; oral ulceration characteristically precedes cutaneous blisters by months Rare / Mild (10–20%) ; cutaneous blisters dominate

Nikolsky's Sign POSITIVE (gentle lateral sliding pressure on perilesional or normal skin induces epidermal shearing/blistering) NEGATIVE (lateral pressure does not shear the epidermis)

Direct Immunofluorescence (DIF) Intercellular IgG and C3 deposition throughout the epidermis in a "chicken-wire" / "fishnet" pattern Continuous linear IgG and C3 deposition along the dermo-epidermal basement membrane zone (BMZ)

Patient Demographics Middle-aged adults ( 40–60 years ); equal gender ratio Elderly adults ( >70 years ); associated with neurological disease (stroke, PD, dementia) and DPP-4 inhibitors (gliptins)

First-Line Management High-dose oral prednisolone (1.0–1.5 mg/kg/day) combined with Rituximab (anti-CD20; first-line disease-modifying therapy); azathioprine or mycophenolate High-potency topical corticosteroids (clobetasol propionate cream 20–40 g/day) to entire body (preferred in elderly to minimize systemic steroid mortality); or oral prednisolone

  • 3. Severe Cutaneous Adverse Reactions (SCARs)
  • Stevens-Johnson Syndrome (SJS) & Toxic Epidermal Necrolysis (TEN)

SJS and TEN are life-threatening mucocutaneous reactions characterized by extensive keratinocyte apoptosis and full-thickness epidermal necrolysis, mediated by cytotoxic CD8+ T-lymphocytes and NK cells releasing granulysin and perforin/granzyme B.

Spectrum Classification by Body Surface Area (BSA) of Epidermal Detachment:

SJS: <10% BSA epidermal detachment.

SJS/TEN Overlap: 10–30% BSA epidermal detachment.

TEN: >30% BSA epidermal detachment.

Clinical Presentation: Onset occurs 1–3 weeks (latency 7–21 days) following initiation of the offending drug. Flu-like prodrome (fever, malaise, sore throat, cough) followed by painful, dusky erythematous macules and atypical targetoid lesions that rapidly coalesce into flaccid bullae. The epidermis sloughs off in sheets, leaving extensive raw, bleeding dermis resembling severe scald burns. Nikolsky's sign is positive . Severe mucosal involvement (≥2 sites in >90%) : hemorrhagic crusted lips, severe stomatitis, pseudomembranous conjunctivitis (risk of symblepharon, corneal scarring, and blindness), and genital/urethral erosions.

Common Culprit Medications: Allopurinol (HLA-B 5801), Carbamazepine (HLA-B 1502 in Han Chinese/SE Asians), Lamotrigine, Phenytoin, Sulfamethoxazole-trimethoprim (Co-trimoxazole), Nevirapine , and oxicam NSAIDs.

SCORTEN Severity-of-Illness Score for SJS/TEN

SCORTEN is a validated prognostic score calculated within the first 24–48 hours of admission. Each parameter scores 1 point:

  • SCORTEN Prognostic Factor Value Indicating 1 Point
  • 1. Age ≥40 years
  • 2. Heart Rate ≥120 beats/min
  • 3. Associated Malignancy Yes (haematologic or solid tumor)
  • 4. Detached Body Surface Area >10% BSA at day 1
  • 5. Serum Urea >10 mmol/L (BUN >28 mg/dL)
  • 6. Serum Bicarbonate <20 mmol/L
  • 7. Serum Glucose >14 mmol/L (>252 mg/dL)

Mortality Prediction: Score 0–1 = 3.2% mortality; Score 2 = 12.1%; Score 3 = 35.3%; Score 4 = 58.3%; Score ≥5 = >90% mortality .

Management: Immediate cessation of all suspect medications; urgent transfer to a specialized Burn Centre or Intensive Care Unit ; supportive fluid resuscitation, ambient temperature maintenance (30–32°C to prevent hypothermia), non-adherent silicone dressings, nutritional support; daily ophthalmology review with aggressive ocular lubrication and symblepharon lysis; immunomodulatory therapies: IVIG, ciclosporin, or anti-TNF (etanercept).

DRESS Syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)

Pathophysiology: Severe drug-induced hypersensitivity accompanied by reactivation of latent human herpesviruses, predominantly Human Herpesvirus 6 (HHV-6) , HHV-7, EBV, and CMV.

Clinical Diagnostic Triad:

Prolonged Latency: Symptoms emerge 2 to 8 weeks after commencing the culprit drug (distinctly slower than SJS/TEN).

Cutaneous & Facial Manifestations: High spiking fever (>38.5°C), widespread confluent morbilliform exanthem, and striking facial oedema (periorbital and facial swelling present in >70%).

Haematological & Visceral Involvement: Marked peripheral eosinophilia (≥1.5 × 10^9/L), atypical lymphocytosis, and internal organ injury:

Hepatitis: Most common organ complication (50–80%), ranging from elevated transaminases to fulminant liver failure.

Nephritis: Acute interstitial nephritis (proteinuria, rising creatinine).

Myocarditis / Pneumonitis: Myocarditis can present insidiously weeks after cutaneous clearing, carrying high mortality.

Culprit Drugs: Allopurinol, carbamazepine, lamotrigine, phenytoin, phenobarbital, sulfasalazine, minocycline, vancomycin.

Management: Immediate cessation of culprit drug; high-dose systemic corticosteroids ( oral prednisolone 0.5–1.0 mg/kg/day or IV methylprednisolone ) with a prolonged, slow taper over 2 to 3 months (rapid tapering precipitates catastrophic rebound flares); serial monitoring of LFTs, troponin, and renal function.

Erythema Nodosum

Pathology: Delayed-type hypersensitivity reaction occurring in subcutaneous adipose tissue; classic histopathology shows septal panniculitis without vasculitis .

Clinical Presentation: Exquisitely tender, painful, warm, erythematous subcutaneous nodules, classically distributed symmetrically over the anterior shins . Lesions do NOT ulcerate and resolve over 3–6 weeks like bruises (erythematous → violaceous → yellowish-green) without scarring. Accompanied by fever, malaise, and ankle arthralgia.

High-Yield Causes:

Streptococcal Pharyngitis: Most common infectious trigger in young adults.

Sarcoidosis: Classic acute presentation: Löfgren's Syndrome (triad of erythema nodosum, bilateral hilar lymphadenopathy on CXR, and acute polyarthritis/ankle periarthritis).

Primary Tuberculosis: Must be ruled out before steroid administration.

Inflammatory Bowel Disease (IBD): Crohn's disease > Ulcerative Colitis. Lesion activity directly parallels luminal bowel inflammation.

Pregnancy & Oral Contraceptive Pills .

Drugs: Sulfonamides, penicillins.